A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.

Pfizer

Status: Completed

Conditions: Cancer of the Kidney; Renal Cancer; Kidney Neoplasms; Kidney Cancer; Cancer of Kidney; Renal Cell Cancer; Renal Cell Carcinoma

Study type: Observational

Funder types: Industry

Identifiers

NCT05363072

FIN-RCC-RWD (Other Identifier)

A4061098

Details and patient eligibility

About

The purpose of the study is to find out how patients with advanced kidney cancer have been treated in the hospital district of Southwest Finland over time.

Enrollment: 1,112 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

For the characteristic group:

• Diagnosis of renal cell carcinoma (International Classification of Diseases 10th revision [ICD]-10:64) during 01 January 2010 and 31 December 2021

For the mRCC group:

• ICD-10 diagnosis code for metastasis (C77*-C79*), or
• American Joint Committee on Cancer (AJCC) stage 4, or AJCC stage data potentially not available for all patients
• Visit to oncologist (specialty code 65) with RCC as main diagnosis, or In Finland, the ICD-10 codes for metastatic disease are rarely used. In contrast, RCC patients visit oncologist, when and only when disease metastasises and therefore, the visit can be used as a proxy to a metastatic disease
• Initiation of treatment for mRCC

Exclusion criteria

For the characteristic group:

• Prevalent mRCC patients (i.e. diagnosis of metastatic RCC before 01 January 2010)
• Prevalent mRCC patients (i.e. diagnosis of RCC before 01 January 2010) if there is no records of metastatic disease during 2010-2021

For the mRCC group:

• Prevalent patients with mRCC (i.e. diagnosis of metastatic RCC before 01 January 2010)
• Patients without treatment for mRCC

Trial design